Open AccessElevated liver enzymes portends a higher rate of complication and death in SARS-CoV-2
Author(s) -
Emily E. Currier,
Mohamad Dabaja,
Syed Mohammed Jafri
Publication year - 2021
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v13.i9.1181
Subject(s) - medicine , elevated liver enzymes , covid-19 , liver enzyme , enzyme , complication , virology , disease , outbreak , biochemistry , pregnancy , chemistry , genetics , infectious disease (medical specialty) , biology
Severe acute respiratory syndrome coronavirus 2, or coronavirus disease-2019 (COVID-19), has infected millions worldwide since its discovery in Wuhan, China in December 2019, but little is still known about the disease process. Preliminary research in China notes liver function tests (LFTs) abnormalities are common in COVID-19 patients, suggesting decreased hepatic function, and that abnormalities in LFTs are related to complicated disease course and negative outcomes. However, there has been limited large-scale data assessing COVID-19's association with liver dysfunction and negative outcomes.